Patients receiving UMEC/VI used statistically significantly less rescue medication during the study compared with those receiving TIO/OLO [Table 2; − 0.25 (95% CI − 0.37 to − 0.14) puffs per day; p < 0.001]
umeclidinium/vilanterol (UMEC/VI)
tiotropium/olodaterol (TIO/OLO)
odds of experiencing a clinically meaningful increase (100 mL or more) from baseline in trough FEV1 at week 8 (patients with COPD)